Clinical trial
2 Doses of an Approved Drug Being Studied for a New Indication for the…
NCT00090246 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00090246 |
|---|---|
| Title | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) |
| Official title | A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postoperative Nausea and Vomiting |
| Intervention type | Drug |
| Interventions | MK0869, aprepitant, Comparator: ondansetron IV |
| Enrollment | 922 |
| Start date | May 13, 2004 |
| Primary completion | Apr 6, 2005 |
| Completion | Apr 20, 2005 |
| First posted | Aug 27, 2004 |
| Last update posted | May 5, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: